[ABT] Abbott: Q3 2026 Earnings Preview: Can Second-Half Growth Accelerate?

Abbott (ABT) runs four businesses: medical devices, diagnostics, nutrition and branded generic medicines sold only outside the United States. Ahead of the Abbott Q3 2026 earnings call scheduled for 2026-10-21, the company is due to report the third quarter of 2026, ending September 30, 2026[1]. The latest disclosed period is the second quarter, when sales were $12.593 billion[2], up 13.0% on a reported basis and 4.8% on a comparable basis, with adjusted EPS of $1.31[3]; the gap between reported and comparable growth comes mainly from Exact Sciences, which was consolidated in March[4]. On July 16 Abbott guided third-quarter adjusted EPS to $1.38 to $1.46, kept its full-year comparable sales growth guidance at 6.5% to 7.5% and set full-year adjusted EPS guidance at $5.45 to $5.60[5], and management said on the call that foreign exchange would reduce third-quarter sales by about 1%[6]. The Drillr earnings calendar shows third-quarter consensus of $1.429 in EPS and $12.956 billion in revenue[1], while stockanalysis.com shows full-year consensus of $5.52 in EPS and $50.20 billion in revenue[7].

Three things are worth watching in this report, and together they answer one question: how a company whose comparable growth was only 3.7% in the first quarter and 4.8% in the second[8] gets to 6.5% to 7.5% for the full year. Management's answer is that 80% of the second-half acceleration comes from four businesses: nutrition, electrophysiology, core laboratory and cancer diagnostics[6]. The first is whether the decline in Nutrition keeps narrowing: comparable sales fell 7.7% in the first quarter[9] and 3.6% in the second, yet U.S. pediatric nutrition was still down 10.7%[10], and the third-quarter figures can separate volume won by price cuts from a temporary lift caused by easier comparisons and channel restocking. The second is whether the cancer diagnostics business bought for about $20.6 billion[11] can pull the Diagnostics segment along: cancer diagnostics grew 13.3% on a comparable basis in the second quarter while the whole segment grew only 2.9%[12], and net interest expense tied to the deal has already reached $299 million a quarter[13]. The third is whether Medical Devices can hold its 8.4% comparable growth[14]: growth in the Libre continuous glucose monitor stalled at 9.5%[15], electrophysiology grew 13.4% and U.S. structural heart fell 0.9%[16], in a segment that produces about 61% of the operating earnings of the four segments[2].

Company Background and Business Structure

Abbott is a diversified healthcare company that reshaped both its portfolio and its balance sheet with one large acquisition in 2026. The company was founded in 1888 and is based in Illinois; it has about 122,000 employees, sells in more than 160 countries, has paid 410 consecutive quarterly dividends and has raised its dividend for 54 consecutive years[5]. On March 23, 2026, Abbott completed the acquisition of Exact Sciences for $105 per share in cash, or about $20.6 billion in total, which took it into cancer screening and precision oncology diagnostics; the deal was funded mainly by $20.0 billion of long-term debt issued that month, with the remainder paid from cash on hand[11].

Medical Devices and Diagnostics are the two largest segments, and both earn their revenue from repeat consumption on top of an installed base or a base of active users. Medical Devices had 2025 sales of $21.387 billion and segment operating earnings of $7.212 billion[17], across seven business lines: diabetes care, electrophysiology, rhythm management, heart failure, vascular, structural heart and neuromodulation[18]. Implantable devices are sold to hospitals and consumed with procedure volume, while FreeStyle Libre sensors are consumables replaced on a fixed cycle; continuous glucose monitor sales were $7.6 billion in 2025[19], and volume depends on the number of active users and on whether national health systems reimburse the product. Diagnostics had 2025 sales of $8.937 billion[17]; the core laboratory business places Alinity instruments with hospitals and independent labs and then sells reagents on an ongoing basis[20], rapid and molecular diagnostics revenue moves with the respiratory virus season[21], and the newly added cancer diagnostics business had second-quarter sales of $919 million[18], mainly from the Cologuard colorectal cancer screening test, along with precision oncology and international businesses[22].

Nutrition and Established Pharmaceuticals are the two businesses closer to consumer goods, and most of Abbott's total revenue comes from outside the United States. Nutrition had 2025 sales of $8.451 billion[17]; the pediatric line includes Similac, PediaSure and Pedialyte, the adult line includes Ensure and Glucerna, and the products are sold through retailers, wholesalers, healthcare facilities and government agencies[19], with a large share of U.S. infant formula reaching low-income families through exclusive state contracts under the WIC program. Established Pharmaceuticals had 2025 sales of $5.536 billion[17], all from outside the United States, mainly from branded generic medicines sold in emerging markets. In the second quarter of 2026, Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals had sales of $5.853 billion, $3.092 billion, $2.144 billion and $1.499 billion, or 46.5%, 24.6%, 17.0% and 11.9% of the total, and sales outside the United States were $7.377 billion, or 58.6%[18].

Financial History and Current Position

Abbott's annual revenue returned to growth after COVID-19 testing faded, and almost all of the increase came from Medical Devices. Company sales were $40.109 billion in 2023, $41.950 billion in 2024 and $44.328 billion in 2025; Medical Devices sales rose from $16.887 billion in 2023 to $21.387 billion in 2025, and its segment operating earnings rose from $5.306 billion to $7.212 billion[17]. Over the same period Diagnostics sales fell from $9.988 billion to $8.937 billion[17] and its operating margin fell from 24.4% to 19.5%, which the company attributed to lower demand for COVID-19 tests and volume-based procurement in China[20]. In 2025 operating cash flow was $9.566 billion and capital expenditure was $2.171 billion[23], and dividends paid were about $4.1 billion[24].

Second-quarter 2026 growth can be read on two bases, and the difference between them is an acquisition. Second-quarter sales were $12.593 billion[2], up 13.0% reported and 4.8% comparable[3], ahead of 3.7% comparable growth in the first quarter[8]; the company's comparable basis includes Exact Sciences sales in both the prior and current year and excludes foreign exchange and the compensation payments its Structural Heart business received from a competitor[25]. The segments diverged widely: comparable growth was 8.4% in Medical Devices, 8.7% in Established Pharmaceuticals and 2.9% in Diagnostics, while Nutrition fell 3.6%[14]. The second-quarter GAAP gross margin was 52.5%, below 52.7% a year earlier, which the company explained by higher intangible amortization from the acquisition[26]; adjusted gross margin was $7.307 billion[27], or 58.0% of sales[28]. GAAP EPS was $0.53 compared with $1.01 a year earlier, and adjusted EPS was $1.31[27] compared with $1.26 a year earlier[29].

The acquisition changed the balance sheet, and interest has become a fixed new cost. In the first half of 2026 Abbott paid $19.962 billion in cash for acquisitions[30]; net interest expense was $299 million in the second quarter, $249 million more than a year earlier, and $367 million in the first half[13]. First-half operating cash flow was $3.803 billion, above $3.464 billion a year earlier, and capital expenditure was $896 million[30]; the quarterly dividend is $0.63 per share[5]. On August 20 Abbott agreed to pay about $670 million to resolve the Gill lawsuit and preterm infant formula claims on behalf of about 2,000 infants, after which about 1,700 lawsuits covering claims for about 12,700 infants remain pending[31].

Operating Model

Abbott's revenue is the product of volume, price and mix in each of the four segments, adjusted for foreign exchange, and each line has a different driver. Implantable and ablation products in Medical Devices are consumed with hospital procedure volume, and new product approvals decide share; Libre sensors are consumables replaced on a fixed cycle, so the $2.188 billion of quarterly diabetes care sales[18] depends mainly on the number of active users, which in turn depends on reimbursement coverage, and the build-up of new users sits between a reimbursement expansion and higher revenue. The core laboratory business in Diagnostics depends on repeat reagent purchases on placed instruments, cancer diagnostics recognizes revenue as tests are completed, and Cologuard revenue comes from both new users and repeat users due for rescreening[22]. Nutrition is a consumer business; the company implemented strategic pricing actions in the fourth quarter of 2025[32], and 2026 revenue depends on whether a volume recovery can offset lower unit prices. The company does not disclose the split between volume and price, so outside observers can only track the outcome through comparable growth and sequential dollar changes.

Operating profit is the sum of segment earnings less corporate costs, share-based compensation, intangible amortization and net interest, and Medical Devices sets its direction. In the second quarter of 2026 Medical Devices had segment operating earnings of $1.969 billion and a 33.6% margin, Established Pharmaceuticals $382 million and 25.5%, Nutrition $368 million and 17.2% (18.9% a year earlier), and Diagnostics $499 million and 16.1% (17.1% a year earlier); the four segments totaled $3.218 billion, of which Medical Devices was 61%[2]. A nutrition price cut lowers unit prices immediately, while the better capacity utilization that comes with recovering volume shows up only with a lag; the Diagnostics margin has been held down by falling respiratory testing and volume-based procurement in China, and although adding Exact Sciences improved the business mix, its R&D and selling expenses were consolidated at the same time[26]. Below the segment line the acquisition added two costs: second-quarter intangible amortization was $658 million[27] compared with $420 million a year earlier[29], and net interest expense was $299 million[13]. Adjusted pre-tax earnings on the company's basis were $2.701 billion[27], and the full-year adjusted EPS guidance already includes $0.20 of dilution from the acquisition[8].

Free cash flow is operating cash flow less capital expenditure, and it goes to dividends, debt repayment and acquisitions in that order, with debt repayment moving up the list after the deal. In 2025 operating cash flow was $9.566 billion and capital expenditure was $2.171 billion[23]; in the first half of 2026 operating cash flow was $3.803 billion, inventories rose by $721 million and capital expenditure was $896 million[30]. Nearly all of the roughly $2.8 billion of Exact Sciences debt that Abbott assumed had been repaid by the end of June[11]. Management said on the call that it plans to invest about $1 billion in a fifth continuous glucose monitor manufacturing facility[33], which will raise future capital expenditure; the settlement of about $670 million reached on August 20 will be a one-time cash outflow, and the company has not disclosed when it will be paid[31].

Industry and Competitive Position

Abbott holds a leading position in several niches, but the competitors and the variables differ in each. In continuous glucose monitoring, management said on the call that there are about 75 million to 80 million eligible patients globally and about 15 million current users[33]. The electrophysiology market is shifting to pulsed field ablation (PFA), and Abbott's Volt and TactiFlex Duo catheters only began ramping in the United States and Europe in 2026[28]; in structural heart, management acknowledged that competition in the U.S. mitral market has intensified and that the company has recently underperformed[34]. In colorectal cancer screening, management said updated American Cancer Society guidelines continue to list Cologuard as a preferred screening option[28]; the potential substitute is blood-based testing, and the company plans to launch its own blood test[33].

Competition in nutrition looks more like consumer goods, and public material offers only a limited basis for comparing share across these markets. The 10-K says competitive factors in nutrition include consumer preferences, advertising, formulation, packaging, scientific innovation, price, retail distribution and product forms[35]; Abbott and Mead Johnson are the only two suppliers of preterm infant formula in the United States, and some of the pending claims name both companies as defendants[31]. Public disclosures contain no audited third-party market share data, so the positions described above all rest on company disclosures and management statements, and readers should treat them as the company's account rather than an independently verified ranking.

Core Debates

After the nutrition price reset, is volume coming back fast enough?

Nutrition is the only one of the four segments that is shrinking, and the speed of its repair decides how large the gap to full-year guidance is. It accounts for about one-sixth of company revenue and is one of the four second-half acceleration sources that management named[6]; full-year comparable growth guidance of 6.5% to 7.5%[5] is well above the 3.7% and 4.8% of the first half, and if Nutrition cannot move from negative growth to roughly flat, the other businesses have a larger gap to fill. The price cuts also lower the segment margin directly, which was 17.2% in the second quarter compared with 18.9% a year earlier[2].

The evidence so far shows a narrowing decline, but the improvement is uneven and supports two readings. The 10-K shows that Nutrition sales grew only 1.1% excluding foreign exchange in 2025 and that U.S. pediatric nutrition fell 2.3%, which the company attributed to lower infant formula sales[36]. Comparable Nutrition sales fell 7.7% in the first quarter of 2026[9], the decline narrowed to 3.6% in the second quarter and sales rose $127 million sequentially[32]; in the second quarter international pediatric nutrition grew 6.4% on a comparable basis and was the first business to turn positive, while U.S. pediatric nutrition still fell 10.7%, U.S. adult fell 6.4% and international adult fell 2.8%[10]. Management said on the July call that Abbott is again the U.S. share leader in both WIC and non-WIC pediatric nutrition and that U.S. adult nutrition retail consumption grew double digits year over year[37]. The other reading is equally valid: part of the narrowing comes from an easier prior-year base and channel restocking, the volume won by lower prices may not last, and the lower unit price is certain; the 10-Q attributes the first-half decline in Nutrition sales to lower volumes in adult nutrition and U.S. pediatric products[21].

The core of this transmission chain is the time gap between a price cut and the volume response, and the third quarter is about whether three numbers improve together. Higher costs in 2025 led to price increases, volume and U.S. infant formula share then fell, and the company began cutting prices and launching new products in the fourth quarter of 2025; only after retail volume and WIC contract share recover does the comparable sales decline narrow and turn positive, and higher output then improves cost absorption and lifts the segment margin from 17.2%. The third-quarter items to watch are whether the comparable decline in Nutrition narrows to within 1.6% and sales are no lower than the second quarter's $2.144 billion[18], whether the decline in U.S. pediatric nutrition narrows meaningfully from 10.7%, and whether the segment operating margin holds 17.2%. If the comparable decline stops narrowing or sales fall sequentially, the second-quarter improvement included restocking; if sales recover while the margin keeps falling, the repair is being bought with price concessions.

Without a new reimbursement expansion, can Libre get back to double-digit growth?

Libre is Abbott's largest single product line, and its slowdown changes where Medical Devices growth comes from. Libre sells more than $2 billion a quarter, about one-sixth of company revenue, and grew 17.4% excluding foreign exchange in 2025[19], which made it the main source of the segment's run of double-digit growth. If the high-single-digit growth of the first half of 2026 becomes the norm, the segment's long-term growth target of 8% to 10%[6] has to be carried by smaller businesses such as electrophysiology, while the company is also planning to invest about $1 billion in a fifth plant[33], a capacity expansion that bets on growth picking up again.

The current evidence is growth stuck in the high single digits, and management and the alternative reading disagree on the cause. Comparable continuous glucose monitor sales grew 7.6% in the first quarter of 2026[38], when management anticipated a return to double-digit growth in the second quarter[39]; the actual second-quarter figure was 9.5%[15], with U.S. diabetes care up 8.6% and international up 9.2% on a comparable basis[16]. Management's explanation is that growth slowed because there was no large reimbursement expansion in this period and that an expansion in any major market would accelerate growth significantly; U.S. Medicare reimbursement for non-insulin type 2 patients could come as early as fall 2026 and would add about 10 million beneficiaries, but the timing cannot be predicted[33]. The alternative reading is that penetration among already reimbursed patients is high, that competing products are present, that the natural growth rate of existing markets has already fallen to the high single digits and that a reimbursement expansion can only raise the base once.

Revenue transmission starts with the reimbursed population, and third-quarter figures can judge only the growth rate of the plateau, not the long-term room for penetration. After national health systems and U.S. Medicare widen the reimbursed population, Libre adds users, sensors are repurchased on a fixed cycle, and the effect then reaches continuous glucose monitor revenue and Medical Devices sales and profit, in a segment with a 33.6% operating margin[2]; without a new round of expansion, growth comes only from penetration within the existing reimbursed population and the international rollout. The third-quarter items to watch are whether comparable continuous glucose monitor growth is at least 10%, whether U.S. and international growth move together, and what management now says about Medicare reimbursement and the U.S. approval timetable for Libre Duo, its dual glucose and ketone sensor. If comparable growth drops below the first quarter's 7.6%, the slowdown is more than a gap between expansions; if the reimbursement timetable slips again, the acceleration anticipated for 2027 falls away.

Can the $20.6 billion Cologuard purchase pull Diagnostics into a second-half acceleration?

Diagnostics is the only Abbott segment whose sales and margin both fell over the past three years, and the financial cost the company accepted to turn it around is already fixed. The segment's operating margin fell from 24.4% in 2023 to 19.5% in 2025[20]; to change that, the company spent about $20.6 billion, added $20.0 billion of debt[11] and accepted $0.20 per share of dilution in 2026[8]. Two of the four second-half acceleration sources named by management sit in Diagnostics[6], and if cancer diagnostics does not accelerate as planned and core laboratory cannot shake off the drag from China, what the acquisition leaves behind in the near term is mainly interest and amortization.

Second-quarter figures show cancer diagnostics growing, but comparable growth for the whole segment is still low. Diagnostics sales rose 42.3% on a reported basis, almost entirely from consolidation, and only 2.9% on a comparable basis[22]; within that, cancer diagnostics grew 13.3%, core laboratory grew 3.2% (7.5% in the United States and 1.7% internationally) and rapid and molecular diagnostics fell 8.0%[12], and the company said Cologuard grew in the mid-teens with both new and repeat users increasing[22]. Management said on the call that full-year cancer diagnostics growth will be higher in the second half than in the first, and that the China core laboratory business, which has declined about 30% over five quarters, should see its decline narrow to the mid-single digits in the second half[6]; management kept its full-year mid-teens growth target for cancer diagnostics, partly because CareGap programs, which help health systems meet quality rating targets, have consistently ramped in the second half[33], and updated American Cancer Society guidelines continue to list Cologuard as a preferred screening option[28]. The alternative reading is that 13% growth is already below the mid-teens full-year target, that the second half needs a clear acceleration to reach it, that competition from blood tests and the company's own sales integration could both disrupt the ramp, and that the core laboratory improvement may be no more than a base effect; the Diagnostics operating margin was 16.1% in the second quarter, below 17.1% a year earlier[2].

Two parallel transmission paths determine Diagnostics sales and margin, and the third quarter can test each of them. On the first path, CareGap programs ramp in the second half and repeat users come due, which raises Cologuard test volume and cancer diagnostics revenue and spreads fixed laboratory costs; on the second, the year-over-year base effect of volume-based procurement in China fades and U.S. contract renewals and share gains add to it, so comparable core laboratory growth speeds up, while respiratory testing in rapid and molecular diagnostics works in the opposite direction. The third-quarter items to watch are whether comparable cancer diagnostics growth is at least 14%, whether international core laboratory growth exceeds 1.7% and management confirms a narrower decline in China, and whether the Diagnostics operating margin holds 16.1%. If cancer diagnostics growth is below 13%, it runs against the plan for a stronger second half; if comparable core laboratory growth is below 3.2%, the drag from China has not faded as anticipated. There are no official quarterly figures for Cologuard test volume or for the split between new and repeat users, so outside observers can rely only on revenue and comparable growth.

Can the new electrophysiology catheters outrun the U.S. mitral slowdown?

Medical Devices is Abbott's profit center, and with Libre slowing, its growth has to be carried by cardiovascular devices. The segment contributes about 46.5% of company revenue[18] and 61% of the operating earnings of the four segments, and its 33.6% operating margin is the highest in the company[2]. Electrophysiology is one of the four second-half acceleration sources named by management[6], and its new catheters have only just entered their ramp; structural heart, by contrast, has turned negative in the United States on a comparable basis, and the prior-year quarter also included $22 million of compensation payments from a competitor[4], with the final payment under that multi-year agreement recognized in the first quarter of 2026[25].

In the second quarter electrophysiology kept growing at a double-digit rate while U.S. structural heart turned negative, so the two are pulling in opposite directions. Electrophysiology grew 13.4% on a comparable basis, 15.9% in the United States and 11.1% internationally[16], compared with 13% in the first quarter[39]; management said Volt 2.0, its next-generation pulsed field ablation catheter, launched in the United States in limited release in the second quarter with full market release planned for the third quarter, that the international rollout of Volt and TactiFlex Duo drove electrophysiology growth of more than 20% in Europe, and that the FDA submission for the Amulet 360 left atrial appendage occluder is complete[28]. Structural heart grew 5.7% on a comparable basis in the second quarter, but U.S. sales fell 0.9% comparable and 9.8% reported, while international sales grew 10.2% comparable[4]; management acknowledged that competitive intensity has increased in the U.S. mitral market, that recent performance has lagged and that commercial execution needs adjusting[34]. Comparable growth for Medical Devices as a whole was 8.4%[14], compared with 8.5% in the first quarter[38]. The alternative reading is that part of the double-digit electrophysiology growth comes from expansion of the atrial fibrillation ablation market itself and from the Amulet products transferred in from Structural Heart at the start of the year[40], that Abbott's new catheters reached the market after competitors' and may not win share even after full release, and that the share loss in mitral could last several quarters.

The net of these two opposing forces, together with Libre and the other businesses, determines Medical Devices sales and margin. Moving Volt 2.0 from limited to full release and rolling out TactiFlex Duo internationally raises Abbott's share and value per atrial fibrillation ablation procedure and speeds up comparable electrophysiology growth; in the other direction, tougher competition in the U.S. mitral market lowers the U.S. procedure share of MitraClip, its mitral repair product, and reduces U.S. structural heart sales. The third-quarter items to watch are whether comparable electrophysiology growth is at least 14% and U.S. growth at least 15.9%, whether the comparable decline in U.S. structural heart stops at 0.9%, and whether the company confirms that Volt 2.0 is in full release and whether the approval timing anticipated for Amulet 360 has changed. If electrophysiology growth is below 12%, the new products have not produced an acceleration; if the U.S. structural heart decline widens, it offsets the electrophysiology gains. The company does not disclose pulsed field ablation catheter volumes or procedure share, so U.S. electrophysiology growth is the closest available proxy.

Risks and Falsifiers

Only part of the cost of the preterm infant formula litigation is fixed, and the remaining claims have no matching reserve in the financial statements. Abbott agreed to pay about $670 million to resolve the Gill lawsuit and claims on behalf of about 2,000 infants; the original Gill verdict was $495 million, or about $600 million with interest, and about 1,700 lawsuits covering claims for about 12,700 infants remain pending[31], while the Missouri Court of Appeals affirmed the Gill verdict in May 2026[41]. The exposure is to cash flow and reported earnings, and the company has not disclosed when the settlement will be paid. The observations that would falsify this concern are a global settlement covering most of the remaining claims, or a run of later trial verdicts for the defense that clearly reduces the number of pending claims.

The financial cost of the acquisition is certain while the growth acceleration is still a plan, and this risk weighs on both the income statement and the use of cash. The $20.0 billion of new long-term debt[11] took net interest expense to $299 million in the second quarter and $367 million in the first half[13], and second-quarter intangible amortization was $658 million[27]; first-half operating cash flow was $3.803 billion and capital expenditure was $896 million[30], annual dividend payments are about $4.1 billion[24], and debt repayment will absorb cash that could otherwise go to buybacks and acquisitions. If cancer diagnostics falls short of mid-teens growth, interest and amortization will keep weighing on reported earnings. There are two falsifying conditions: the company discloses clear progress on debt repayment in the third quarter with net interest expense no higher than the second quarter's $299 million, and comparable cancer diagnostics growth is at least 14% in the third quarter with the full-year mid-teens plan maintained.

Foreign exchange affects reported revenue and profit at the same time, because about 58.6% of company sales come from outside the United States[18]. Foreign exchange added 0.8% to total sales in the second quarter, the difference between 13.0% reported growth and 12.2% excluding foreign exchange[14]; management projects an effect of about negative 1% on third-quarter sales and about positive 1% for the full year[6]. If the third-quarter effect is no worse than negative 1% and the company does not lower full-year EPS guidance because of currency, this risk has not materialized in the quarter.

Nutrition and Libre face the same kind of risk: the side the company has already paid for or cannot control is certain, and the payoff side is not. The nutrition price cuts have already happened, and if consumers respond less than the company anticipated, the segment loses both unit price and margin; on second-quarter sales of $2.144 billion and segment operating earnings of $368 million[2], one percentage point of comparable growth is worth about $22 million and each percentage point of margin is worth about $21 million of quarterly operating earnings, and the falsifying condition is a third-quarter comparable decline within 1.6% with a segment margin no lower than 17.2%. The timing of Libre reimbursement expansions is decided by national health systems and the U.S. CMS, not by the company, and management acknowledges that it cannot pin an expansion to a specific quarter[34]; continuous glucose monitor sales exceed $2 billion a quarter, so one percentage point of growth is worth about $20 million, and the falsifying condition is third-quarter comparable growth of at least 10%, or U.S. Medicare reimbursement for non-insulin type 2 patients formally taking effect during 2026.

What to Watch Next

• Nutrition volume repair: comparable Nutrition sales fell 3.6% and U.S. pediatric nutrition fell 10.7% in the second quarter of 2026[10], with a 17.2% segment operating margin[2]. Watch whether the decline keeps narrowing and sales stay at or above $2.144 billion; a decline within 1.6% with the margin at or above 17.2% confirms the repair, while a stalled decline or a sequential drop in sales falsifies it.
• Libre growth: comparable continuous glucose monitor growth was 9.5% in the second quarter of 2026[15], with the United States at 8.6% and international at 9.2%[16]. Watch whether growth returns to 10% and what the company says about the Medicare reimbursement and Libre Duo timetables; growth of at least 10% or a reimbursement decision confirms, while growth below 7.6% or a further delay falsifies.
• Second-half acceleration in Diagnostics: comparable growth was 13.3% in cancer diagnostics and 3.2% in core laboratory in the second quarter of 2026[12], with a 16.1% segment operating margin[2]. Watch whether cancer diagnostics accelerates and whether the China decline narrows to the mid-single digits; cancer diagnostics growth of at least 14% with the margin holding 16.1% confirms, while growth below 13% or core laboratory growth below 3.2% falsifies.
• Electrophysiology and U.S. mitral: in the second quarter of 2026 comparable electrophysiology growth was 13.4%, U.S. electrophysiology growth was 15.9% and U.S. structural heart fell 0.9%[16]. Watch whether Volt 2.0 reaches full release and whether the Amulet 360 approval timing changes; electrophysiology growth of at least 14% with U.S. mitral stabilizing confirms, while growth below 12% or a wider U.S. decline falsifies.
• Leverage after the acquisition: net interest expense was $299 million in the second quarter of 2026[13]. Watch whether the company discloses debt repayment progress; net interest expense no higher than $299 million confirms.
• Full-year guidance: comparable sales growth was 4.8% in the second quarter[3], and third-quarter adjusted EPS guidance is $1.38 to $1.46[5]. Watch where third-quarter comparable growth sits relative to the 6.5% to 7.5% full-year range, whether the foreign exchange effect is about negative 1%, and whether the company maintains or changes its full-year guidance.

Conclusion

Abbott's profit is set mainly by Medical Devices, while the full-year target depends on four weaker or newer businesses accelerating at the same time. The four segments produced $3.218 billion of operating earnings in the second quarter, 61% of it from Medical Devices[2]; comparable growth was 4.8% and adjusted EPS was $1.31[3], yet full-year comparable growth guidance of 6.5% to 7.5%[5] requires a second half that is clearly faster than the first. The central unresolved relationship is that the costs of price cuts, the acquisition and capacity expansion are already fixed, with quarterly net interest expense of $299 million[13] and a 17.2% Nutrition segment margin[2] already in the accounts, while the payoff from nutrition volume, the Cologuard ramp, Libre reimbursement expansion and new electrophysiology products still has to be proven in later quarters.

Only two independent assessments published after the second-quarter results could be verified word for word, so outside coverage is thin, and both should be read as outside interpretations rather than facts. GuruFocus, in its earnings call highlights on the day of the results, listed the acceleration in comparable growth to 4.8%, adjusted EPS of $1.31 and the raised full-year EPS guidance as positives, and listed four negatives: an 8% decline in rapid and molecular diagnostics, greater competitive intensity in the U.S. mitral market, a continued decline forecast for the China business because of volume-based procurement, and growth in continuous glucose monitoring that "has plateaued at 9.5%, with future acceleration dependent on reimbursement expansions"[42]. Those four points map to the Diagnostics, electrophysiology and mitral, and Libre debates; its wording on Libre matches management's plateau explanation and does not address the alternative reading that the natural growth rate of existing markets has already fallen. Vardah Gill of Insider Monkey, assessing the preterm infant formula settlement on August 24, wrote: "The bigger issue for investors is that the settlement does not fully end the litigation." The article said claims from as many as 12,700 people remain, a figure that includes duplicate and unsupported claims as well as cases where it is unclear which manufacturer's formula was used; the article also noted that the settlement could put a meaningful portion of the legal risk behind the company and that the products at issue are specialized formulas used in hospitals for premature infants, not the ordinary infant formula sold in stores[43]. The two assessments do not conflict, since the first looks at operating growth and the second at litigation; neither discusses the repair in nutrition volume or the interest burden after the acquisition, and those are the two gaps in outside coverage.

The combination of later observations that would clearly strengthen the current understanding is a comparable decline in Nutrition within 1.6% with a segment margin no lower than 17.2%, comparable cancer diagnostics growth of at least 14%, comparable continuous glucose monitor growth back at 10% or U.S. Medicare reimbursement taking effect, comparable electrophysiology growth of at least 14% with U.S. structural heart stabilizing, and net interest expense no higher than $299 million. The combination that would clearly weaken it is a sequential drop in Nutrition sales, cancer diagnostics growth below 13%, continuous glucose monitor growth below 7.6%, electrophysiology growth below 12% and a cut to full-year comparable growth guidance. These observations have to be read together, because an improvement in any single business is not enough to lift first-half growth into the full-year guidance range.

Sources

[1] Drillr earning_call_calendar · ABT 2026-10-21 (last updated 2026-09-20) · 2026-09-20 · Drillr earning_call_calendar

[2] ABT 10-Q filed 2026-07-28 · segment operating earnings 2Q26 · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[3] ABT 8-K filed 2026-07-16 · 2Q26 highlights and guidance · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[4] ABT 8-K filed 2026-07-16 · comparable sales reconciliation 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[5] ABT 8-K filed 2026-07-16 · financial guidance · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[6] ABT earnings call 2026-07-16 · guidance · 2026-07-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[7] stockanalysis.com ABT forecast (updated 2026-09-14) · 2026-09-14 · stockanalysis.com(S&P Global Market Intelligence) · https://stockanalysis.com/stocks/abt/forecast/

[8] ABT 8-K filed 2026-04-16 · 1Q26 highlights and guidance · 2026-04-16 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800&type=8-K&dateb=&owner=include&count=40

[9] ABT 8-K filed 2026-04-16 · Nutrition commentary 1Q26 · 2026-04-16 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800&type=8-K&dateb=&owner=include&count=40

[10] ABT 8-K filed 2026-07-16 · Nutrition comparable growth 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[11] ABT 10-Q filed 2026-07-28 · Exact Sciences acquisition · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[12] ABT 8-K filed 2026-07-16 · Diagnostics comparable growth 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[13] ABT 10-Q filed 2026-07-28 · interest expense · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[14] ABT 8-K filed 2026-07-16 · comparable growth by segment 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[15] ABT 8-K filed 2026-07-16 · Medical Devices commentary 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[16] ABT 8-K filed 2026-07-16 · Medical Devices comparable growth 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[17] ABT 10-K filed 2026-02-20 · segment sales and operating earnings 2023-2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[18] ABT 10-Q filed 2026-07-28 · sales by business 2Q26 · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[19] ABT 10-K filed 2026-02-20 · CGM sales 2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[20] ABT 10-K filed 2026-02-20 · Diagnostics 2025 operating earnings · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[21] ABT 10-Q filed 2026-07-28 · first-half sales drivers · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[22] ABT 8-K filed 2026-07-16 · Diagnostics commentary 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[23] ABT 10-K filed 2026-02-20 · cash flow statement 2023-2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[24] ABT 10-K filed 2026-02-20 · dividends and repurchases · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[25] ABT 8-K filed 2026-07-16 · comparable sales definition · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[26] ABT 10-Q filed 2026-07-28 · gross margin, R&D and SG&A · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[27] ABT 8-K filed 2026-07-16 · 2Q26 non-GAAP reconciliation · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[28] ABT earnings call 2026-07-16 · management highlights · 2026-07-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[29] ABT 8-K filed 2026-07-16 · 2Q25 non-GAAP reconciliation · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[30] ABT 10-Q filed 2026-07-28 · cash flow first half 2026 · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[31] ABT 8-K filed 2026-08-20 · NEC settlement · 2026-08-20 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800&type=8-K&dateb=&owner=include&count=40

[32] ABT 8-K filed 2026-07-16 · Nutrition commentary 2Q26 · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[33] ABT earnings call 2026-07-16 · analyst Q&A · 2026-07-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[34] ABT earnings call 2026-07-16 · risks · 2026-07-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[35] ABT 10-K filed 2026-02-20 · nutrition marketing and competition · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[36] ABT 10-K filed 2026-02-20 · Nutritional Products 2025 sales · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/

[37] ABT earnings call 2026-07-16 · segment performance · 2026-07-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[38] ABT 8-K filed 2026-04-16 · Medical Devices commentary 1Q26 · 2026-04-16 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800&type=8-K&dateb=&owner=include&count=40

[39] ABT earnings call 2026-04-16 · segment performance · 2026-04-16 · earnings-call · https://www.abbottinvestor.com/events-and-presentations

[40] ABT 8-K filed 2026-07-16 · Amulet transfer to Electrophysiology · 2026-07-16 · 8-K · https://abbott.mediaroom.com/2026-07-16-Abbott-Reports-Second-Quarter-2026-Results-and-Raises-Full-Year-EPS-Guidance

[41] ABT 10-Q filed 2026-07-28 · NEC litigation · 2026-07-28 · 10-Q · https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/

[42] GuruFocus 2026-07-16 · Abbott Q2 2026 Earnings Call Highlights · 2026-07-16 · GuruFocus · https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-q2-2026-210023231.html

[43] Insider Monkey 2026-08-24 · Abbott Pays $670 Million to Settle Formula Claims as Legal Risks Persist · 2026-08-24 · Insider Monkey · https://www.insidermonkey.com/blog/abbott-pays-670-million-to-settle-formula-claims-as-legal-risks-persist-1821816/